RG
BLCM

Redmile Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Redmile Group’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-23,812
Closed -$5.07M – 68
2015
Q2 		$5.07M Sell
23,812
-20,710
-47% -$5.08M 0.42% 45
2015
Q1 		$9.28M Sell
44,522
-41,559
-48% -$10.1M 0.83% 41
2014
Q4 		$17.3M Buy
+86,081
New +$18.5M 1.88% 21

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Redmile Group's BLCM Position: Q3 2015 in Review

Redmile Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2015, closing a stake of 23,812 shares — an estimated $5.07M sold.

Redmile Group first reported a position in BLCM in Q4 2014 and held it in 3 quarters. The position peaked at $17.3M in Q4 2014. 83 funds tracked by Wall St. Rank hold BLCM as of Q3 2015.

  • Redmile Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Redmile Group sold 23,812 Bellicum Pharmaceuticals, Inc. shares in Q3 2015, an estimated $5.07M.
  • Redmile Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 3 quarters.
  • Redmile Group's Bellicum Pharmaceuticals, Inc. position peaked at $17.3M in Q4 2014.
  • 83 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2015.

Based on Redmile Group's 13F filing for Q3 2015, filed 17 Nov 2015.